MLI Stock Chart & Stats
€109.00
€0.50(0.59%)
At close: 4:00 PM EDT
€109.00
€0.50(0.59%)
Day’s Range― - ―
52-Week Range€50.50 - €111.00
Previous CloseN/A
Volume0.00
Average Volume (3M)10.00
Market Cap
€614.62M
Enterprise Value€703.77
Total Cash (Recent Filing)€30.70M
Total Debt (Recent Filing)€101.36M
Price to Earnings (P/E)148.6
Beta0.87
Next Earnings
Nov 05, 2026EPS Estimate
1.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.86
Shares Outstanding5,595,869
10 Day Avg. Volume0
30 Day Avg. Volume10
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)2.62
Price to Sales (P/S)1.96
P/FCF Ratio12.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€94.72Price Target Upside-13.10% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)8.83
Revenue Forecast (FY)€221.38M
Bulls Say, Bears Say
Bulls Say
Recurring Regulated DemandMesa serves regulated healthcare, pharmaceutical, medical device, and laboratory customers that must continuously validate processes and document compliance. Its consumables and periodic calibration services therefore support repeat purchasing, creating a durable revenue foundation beyond one-time instrument sales.
Strong Cash GenerationStrong operating and free cash flow indicate that Mesa is converting its business activity into funding for debt reduction, investment, and shareholder needs. FCF growth of 31% and close alignment with net income also suggest cash generation is not primarily accounting-driven.
Margin And Operating ImprovementImproving gross profit and adjusted operating income show that management is gaining operating leverage despite uneven segment performance. Higher margins can strengthen internal funding capacity and provide a more durable earnings base if efficiency and product-mix gains persist.
Bears Say
Thin, Volatile ProfitabilityMesa's limited bottom-line margin leaves earnings vulnerable to modest changes in volume, mix, costs, or non-operating items. The history of a very large annual loss also indicates that current improvement has not yet established consistently durable profitability or strong shareholder returns.
SDC Fulfillment Execution RiskSDC is a major contributor, so missed ship dates can affect consolidated revenue and customer confidence rather than merely one small product line. Persistent fulfillment problems may also allow customers to evaluate alternatives, making execution improvement important to protecting durable market position.
China Clinical Genomics WeaknessThe China weakness appears more structural than a single-quarter fluctuation, and management has already reduced exposure over the past two years. Continued regional pressure can limit Clinical Genomics growth and constrain the contribution from an otherwise strategically important quality-control business.
Mesa Laboratories News
MLI FAQ
What was Mesa Laboratories’s price range in the past 12 months?
Mesa Laboratories lowest stock price was €50.50 and its highest was €111.00 in the past 12 months.
What is Mesa Laboratories’s market cap?
Mesa Laboratories’s market cap is €614.62M.
When is Mesa Laboratories’s upcoming earnings report date?
Mesa Laboratories’s upcoming earnings report date is Nov 05, 2026 which is in 57 days.
How were Mesa Laboratories’s earnings last quarter?
Mesa Laboratories released its earnings results on Aug 10, 2026. The company reported €2.325 earnings per share for the quarter, beating the consensus estimate of €2.278 by €0.048.
Is Mesa Laboratories overvalued?
According to Wall Street analysts Mesa Laboratories’s price is currently Overvalued.
Does Mesa Laboratories pay dividends?
Mesa Laboratories does not currently pay dividends.
What is Mesa Laboratories’s EPS estimate?
Mesa Laboratories’s EPS estimate is 1.38.
How many shares outstanding does Mesa Laboratories have?
Mesa Laboratories has 5,595,869 shares outstanding.
What happened to Mesa Laboratories’s price movement after its last earnings report?
Mesa Laboratories reported an EPS of €2.325 in its last earnings report, beating expectations of €2.278. Following the earnings report the stock price went down -0.571%.
Which hedge fund is a major shareholder of Mesa Laboratories?
Currently, no hedge funds are holding shares in DE:MLI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mesa Laboratories Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€94.72 (-13.10% Downside)
€94.72 (-13.10% Downside)
Blogger Sentiment
Bullish
DE:MLI Sentiment 100%
Sector Average 60%
Sector Average 60%
Insider Transactions
Sold Shares
Worth €323.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
99.92%
12-Months-Change
Fundamentals
Return on Equity
0.51%
Trailing 12-Months
Asset Growth
-3.79%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mesa Laboratories
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
MLI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced clear operational progress and improving financial metrics (modest revenue growth, margin expansion, AOI improvement, strong cash flow and debt reduction) with material execution challenges in SDC (quarterly revenue decline, delivery reliability and backlog volatility) and some non-operating volatility from currency impacts. Management presented a concrete remediation plan (operations focus, R&D reprioritization for Gyrolab, new commercial leadership in BPD) and committed to delivering full-year guidance in November, suggesting confidence in a fixable path forward.View all DE:MLI earnings summariesMLI Stock 12 Month Forecast
Average Price Target
€94.72
▼(-13.10% Downside)
Technical Analysis
Daktronics
―
Lightpath Technologies
―
Lsi Industries
―
Richardson Electronics
―
Vishay Precision Group
―